{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"CD47 is a cell-surface protein expressed on multiple normal cell types and often at high levels on many malignant tumour cells .","groups":[{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.05 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.05 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.1 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.1 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.2 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG002","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.2 mg/kg"},{"description":"Participants with advanced relapsed or refractory lymphomas received TTI-621 0.3 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG003","title":"Part 1: Ontorpacept (PF-07901800/TTI-621) 0.3 mg/kg"}],"populationDescription":"This outcome measure was not analyzed since CD47 data for Part 1 was not collected as the assay was not set up when enrolling the Part 1 participants. Hence, no participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Part 1: Week 1 end of infusion (EOI)","title":"Part 1: Percentage of CD47 Receptor Occupancy on Peripheral Blood CD3+ Cells","type":"SECONDARY"}